IMS Health Holdings, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- IPO Date
- Apr 3, 2014
- CIK
- 0001595262
- Similar Companies
- Business
- IMS Health Holdings, Inc. operates as a global information and technology services company serving the healthcare industry. The company offers comprehensive data and analytics services including pharmaceutical and medical device market intelligence, patient-level data, physician prescribing data, clinical trial analytics, technology and consulting services. Its core products encompass healthcare data integration and analytics platforms, cloud-based software solutions like IMS One for business analytics, commercial operations support, sales force effectiveness tools, multi-channel marketing, lifecycle management, and payer-provider contracting and performance management solutions. IMS Health primarily serves pharmaceutical, biotechnology, consumer health manufacturers, distributors, providers, payers, government agencies, and researchers across the United States and international markets. IMS Health was founded in 1954 and is headquartered in Danbury, Connecticut. The company has expanded through acquisitions such as SDI Health in the U.S. and Ardentia Ltd in the U.K., enhancing its specialty and patient-level data capabilities. In 2016, IMS Health merged with Quintiles Transnational Holdings Inc., creating QuintilesIMS (now IQVIA), combining healthcare information with contract research and technology services to address the full life sciences product lifecycle from R&D through commercial execution to patient outcomes. Recent changes include the integration and operational consolidation of services under the IQVIA brand, enhancing technology service offerings including cloud infrastructure and analytics, with a focus on driving efficiencies across global healthcare operations. IMS Health’s solutions leverage extensive global healthcare datasets exceeding 10 petabytes, connecting disease, treatment, cost, and outcome data via proprietary analytics hosted on its intelligent cloud platform. The company’s ongoing strategic expansion targets broader healthcare industry needs, including clinical trial design and execution tools, payer services optimization, and real-world evidence generation. This positions IMS Health as a critical partner in healthcare decision-making processes worldwide, leveraging technology and data to improve healthcare performance and outcomes. The company operates in over 100 countries and maintains dual headquarters in Danbury, Connecticut, and Research Triangle Park, North Carolina. Its recent strategic focus emphasizes enhancing commercial, operational, and financial synergies through technology integration and expanding its market reach in emerging and developed healthcare markets globally. IMS Health Holdings, Inc. is recognized as a leading provider of healthcare information, technology, and services, innovating in areas such as data analytics, cloud solutions, and life sciences research support to serve a wide range of healthcare stakeholders, including life sciences companies, healthcare providers, payers, and governments. The company’s evolution through mergers, acquisitions, and technology upgrades reflects its commitment to advancing healthcare delivery and decision-making.
Company News
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
MACOM and Elve to Demonstrate a V-Band Linearized TWTA for Satellite Communications and Defense Applications at IMS 2026
Guerrilla RF Announces Expanded Focus on Tactical Radio Market, Debuts New Solutions Guide at IMS2026
MACOM IMS 2026 Product Announcements for Satellite Communications
MACOM IMS 2026 Product Announcements for Aerospace and Defense
Aramark Sports + Entertainment Drives New Food & Beverage and Premium Hospitality Experiences at Indianapolis Motor Speedway for 2026
IMS Announces Executive AEO Training to Help Companies Increase Visibility Across Generative AI Platforms Including ChatGPT, Claude, Grok, and Perplexity
Charles River Wealth to Expand Capabilities Supporting Private Assets within Unified Managed Accounts (UMA)
Vitalist Engages IMS Investor Relations to Enhance Capital Markets Presence
Broadcom Inc. $AVGO Shares Purchased by Analyst IMS Investment Management Services Ltd.
Is Wix.com a Buy After Financial Services Company Analyst IMS Expands Its Position in the Stock?
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
Will IMS Unit's Poor Performance Hit L3Harris Technologies Q2 Earnings?
Tower Semiconductor and pSemi Win the Prestigious Industry Paper Competition Award at IMS 2025
MACOM IMS 2025 Product Preview – Satellite Communications
MACOM IMS 2025 Product Preview – Radar
MACOM IMS 2025 Product Preview – Electronic Countermeasures